{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:49:06Z","timestamp":1790776146442,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T00:00:00Z","timestamp":1254182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s11892-009-0058-x","type":"journal-article","created":{"date-parts":[[2009,9,28]],"date-time":"2009-09-28T09:47:41Z","timestamp":1254131261000},"page":"368-375","source":"Crossref","is-referenced-by-count":17,"title":["What are the risks and the benefits of current and emerging weight-loss medications?"],"prefix":"10.1007","volume":"9","author":[{"given":"Jamie R.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,29]]},"reference":[{"key":"58_CR1","volume-title":"Obesity: Preventing and Managing the Global Epidemic","author":"World Health Organization","year":"1998","unstructured":"World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Geneva: World Health Organization; 1998."},{"key":"58_CR2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1753944708098226","volume":"3","author":"E. Idelevich","year":"2009","unstructured":"Idelevich E, Kirch W, Schindler C: Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 2009, 3:75\u201390.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"58_CR3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ecl.2008.08.004","volume":"37","author":"G.A. Bray","year":"2008","unstructured":"Bray GA: Medications for weight reduction. Endocrinol Metab Clin North Am 2008, 37:923\u2013942.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"58_CR4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/14728220802637063","volume":"13","author":"R. Chakrabarti","year":"2009","unstructured":"Chakrabarti R: Pharmacotherapy of obesity: emerging drugs and targets. Expert Opin Ther Targets 2009, 13:195\u2013207.","journal-title":"Expert Opin Ther Targets"},{"key":"58_CR5","unstructured":"Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. National Institutes of Health [no authors listed]. Obes Res 1998, 6(Suppl 2):51S\u2013209S."},{"key":"58_CR6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","volume":"369","author":"R.S. Padwal","year":"2007","unstructured":"Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71\u201377.","journal-title":"Lancet"},{"key":"58_CR7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1517\/14740338.4.6.1083","volume":"4","author":"F.L. Greenway","year":"2005","unstructured":"Greenway FL, Caruso MK: Safety of obesity drugs. Expert Opin Drug Saf 2005, 4:1083\u20131095.","journal-title":"Expert Opin Drug Saf"},{"key":"58_CR8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1463-1326.2008.00930.x","volume":"11","author":"A.M. Sharma","year":"2009","unstructured":"Sharma AM, Caterson ID, Coutinho W, et al.: Blood pressure changes associated with sibutramine and weight management: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2009, 11:239\u2013250.","journal-title":"Diabetes Obes Metab"},{"key":"58_CR9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1023\/A:1011808701117","volume":"2","author":"G.A. Bray","year":"2001","unstructured":"Bray GA: Drug treatment of obesity. Rev Endocr Metab Disord 2001, 2:403\u2013418.","journal-title":"Rev Endocr Metab Disord"},{"key":"58_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","volume":"4","author":"A. Gokcel","year":"2002","unstructured":"Gokcel A, Gumurdulu Y, Karakose H, et al.: Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab 2002, 4:49\u201355.","journal-title":"Diabetes Obes Metab"},{"key":"58_CR11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1742-1241.2008.01980.x","volume":"63","author":"J. Philippe","year":"2009","unstructured":"Philippe J, Raccah D: Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract 2009, 63:321\u2013332.","journal-title":"Int J Clin Pract"},{"key":"58_CR12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/msj.20116","volume":"76","author":"O.R. Hamnvik","year":"2009","unstructured":"Hamnvik OR, McMahon GT: Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med 2009, 76:234\u2013243.","journal-title":"Mt Sinai J Med"},{"key":"58_CR13","doi-asserted-by":"crossref","unstructured":"Park MH, Kinra S, Ward KJ, et al.: Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009 Jun 5 (Epub ahead of print).","DOI":"10.2337\/dc09-0258"},{"key":"58_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","volume":"113","author":"E. Carrizo","year":"2009","unstructured":"Carrizo E, Fernandez V, Connell L, et al.: Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009, 113:19\u201326.","journal-title":"Schizophr Res"},{"key":"58_CR15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2265.2008.03396.x","volume":"70","author":"A.H. Barnett","year":"2009","unstructured":"Barnett AH: New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol 2009, 70:343\u2013353.","journal-title":"Clin Endocrinol"},{"key":"58_CR16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1463-1326.2006.00602.x","volume":"8","author":"L. Blonde","year":"2006","unstructured":"Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436\u2013447.","journal-title":"Diabetes Obes Metab"},{"key":"58_CR17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14740330802432003","volume":"7","author":"S.C. Bain","year":"2008","unstructured":"Bain SC, Stephens JW: Exenatide and pancreatitis: an update. Expert Opin Drug Saf 2008, 7:643\u2013644.","journal-title":"Expert Opin Drug Saf"},{"key":"58_CR18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","volume":"25","author":"D.D. Dore","year":"2009","unstructured":"Dore DD, Seeger JD, Arnold Chan K: Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019\u20131027.","journal-title":"Curr Med Res Opin"},{"key":"58_CR19","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","volume":"31","author":"S.R. Smith","year":"2008","unstructured":"Smith SR, Aronne LJ, Burns CM, et al.: Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008, 31:1816\u20131823.","journal-title":"Diabetes Care"},{"key":"58_CR20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/0063030-200822060-00004","volume":"22","author":"S. Edelman","year":"2008","unstructured":"Edelman S, Maier H, Wilhelm K: Pramlintide in the treatment of diabetes mellitus. BioDrugs 2008, 22:375\u2013386.","journal-title":"BioDrugs"},{"key":"58_CR21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1463-1326.2008.01026.x","volume":"11","author":"S. Choussein","year":"2009","unstructured":"Choussein S, Makri AA, Frangos CC, et al.: Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:641\u2013664.","journal-title":"Diabetes Obes Metab"},{"key":"58_CR22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2008.11.014","volume":"278","author":"A. Alberici","year":"2009","unstructured":"Alberici A, Borroni B, Manelli F, et al.: Topiramate weight loss in migraine patients. J Neurol Sci 2009, 278:64\u201365.","journal-title":"J Neurol Sci"},{"key":"58_CR23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1345\/aph.1K520","volume":"42","author":"E.C. Cates","year":"2008","unstructured":"Cates EC, Feldman JM, Boggs AA, et al.: Efficacy of add-on topiramate therapy in psychiatric patients with weight gain. Ann Pharmacother 2008, 42:505\u2013510.","journal-title":"Ann Pharmacother"},{"key":"58_CR24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp.2007.136929","volume":"79","author":"K.M. Klein","year":"2008","unstructured":"Klein KM, Theisen F, Knake S, et al.: Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psychiatry 2008, 79:590\u2013593.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"58_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00023210-200923020-00004","volume":"23","author":"S.L. McElroy","year":"2009","unstructured":"McElroy SL, Guerdjikova AI, Martens B, et al.: Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009, 23:139\u2013156.","journal-title":"CNS Drugs"},{"key":"58_CR26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/14728214.13.2.383","volume":"13","author":"C.T. Supuran","year":"2008","unstructured":"Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008, 13:383\u2013392.","journal-title":"Expert Opin Emerg Drugs"},{"key":"58_CR27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.yebeh.2006.02.001","volume":"8","author":"W.A. Tosches","year":"2006","unstructured":"Tosches WA, Tisdell J: Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006, 8:522\u2013526.","journal-title":"Epilepsy Behav"},{"key":"58_CR28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","volume":"10","author":"J.W. Anderson","year":"2002","unstructured":"Anderson JW, Greenway FL, Fujioka K, et al.: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002, 10:633\u2013641.","journal-title":"Obes Res"},{"key":"58_CR29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00003495-200262002-00005","volume":"62","author":"H.J. Aubin","year":"2002","unstructured":"Aubin HJ: Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002, 62:45\u201352.","journal-title":"Drugs"},{"key":"58_CR30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1517\/14656560902775750","volume":"10","author":"R.A. Plodkowski","year":"2009","unstructured":"Plodkowski RA, Nguyen Q, Sundaram U, et al.: Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 2009, 10:1069\u20131081.","journal-title":"Expert Opin Pharmacother"},{"key":"58_CR31","unstructured":"European Medicines Agency: The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Available at http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/acomplia\/53777708en.pdf . Accessed June 2009."},{"key":"58_CR32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1467-789X.2008.00520.x","volume":"10","author":"F. Akbas","year":"2009","unstructured":"Akbas F, Gasteyger C, Sjodin A, et al.: A critical review of the cannabinoid receptor as a drug target for obesity management. Obesity 2009, 10:58\u201367.","journal-title":"Obesity"},{"key":"58_CR33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1098-3597(08)60028-9","volume":"9","author":"L.J. Aronne","year":"2008","unstructured":"Aronne LJ, Pagotto U, Foster GD, Davis SN: The endocannabinoid system as a target for obesity treatment. Clin Cornerstone 2008, 9:52\u201366.","journal-title":"Clin Cornerstone"},{"key":"58_CR34","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(08)61525-1","volume":"372","author":"A. Astrup","year":"2008","unstructured":"Astrup A, Madsbad S, Breum L, et al.: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1906\u20131913.","journal-title":"Lancet"},{"key":"58_CR35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.2008.164269","volume":"587Pt1","author":"D. Karra","year":"2009","unstructured":"Karra D, Chandarana K, Batterham R: The role of peptide YY in appetite regulation and obesity. J Physiol 2009, 587(Pt 1):19\u201325.","journal-title":"J Physiol"},{"key":"58_CR36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.physbeh.2009.02.024","volume":"97","author":"M.T. Neary","year":"2009","unstructured":"Neary MT, Batterham RL: Peptide YY: food for thought. Physiol Behav 2009, 97:616\u2013619.","journal-title":"Physiol Behav"},{"key":"58_CR37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2007.00807.x","volume":"10","author":"N. White","year":"2008","unstructured":"White Ne, Dhillo WS, Liu YL, et al.: Co-administration of SR141716 with peptide YY(3-36) or oxyntomodulin had additive effects on food intake in mice. Diabetes Obes Metab 2008, 10:167\u2013170.","journal-title":"Diabetes Obes Metab"},{"key":"58_CR38","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/en.2005-0237","volume":"146","author":"N.M. Neary","year":"2005","unstructured":"Neary NM, Small CJ, Druce MR, et al.: Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005, 146:5120\u20135127.","journal-title":"Endocrinology"},{"key":"58_CR39","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1053\/j.gastro.2005.09.001","volume":"129","author":"L. Degen","year":"2005","unstructured":"Degen L, Oesch S, Casanova M, et al.: Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005, 129:1430\u20131436.","journal-title":"Gastroenterology"},{"key":"58_CR40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2125.2008.03311.x","volume":"67","author":"A. Bryson","year":"2009","unstructured":"Bryson A, de la Motte S, Dunk C: Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol 2009, 67:309\u2013315.","journal-title":"Br J Clin Pharmacol"},{"key":"58_CR41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/oby.2008.537","volume":"17","author":"S.R. Smith","year":"2009","unstructured":"Smith SR, Prosser WA, Donahue DJ, et al.: Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women. Obesity 2009, 17:494\u2013503.","journal-title":"Obesity"},{"key":"58_CR42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","volume":"325","author":"W.J. Thomsen","year":"2008","unstructured":"Thomsen WJ, Grottick AJ, Menzaghi F, et al.: Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008, 325:577\u2013587.","journal-title":"J Pharmacol Exp Ther"},{"key":"58_CR43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/dot.2009.45.2.1336104","volume":"45","author":"T. Vilsboll","year":"2009","unstructured":"Vilsboll T: Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 2009, 45:101\u2013113.","journal-title":"Drugs Today (Barc)"},{"key":"58_CR44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","volume":"11","author":"I. Idris","year":"2009","unstructured":"Idris I, Donnelly R: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, 11:79\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"58_CR45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"F.L. Greenway","year":"2008","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, et al.: Rational design of a combination medication for the treatment of obesity. Obesity 2008, 17:30\u201339.","journal-title":"Obesity"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0058-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-009-0058-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0058-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T20:02:15Z","timestamp":1710619335000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-009-0058-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,29]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s11892-009-0058-x","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,29]]}}}